Hospital Universitario De Jaen — Clinical Trial Site

131 Registered trials

50 Currently recruiting

Organisation

Hospital Universitario De Jaen

Location

Jaen, Spain

Identifier

ORG-100041196

Address

Avenida Del Ejercito Espanol 10, 23007, Spain

Departments

034028: Oncología Médica
1201: Oncología Médica
1212:Oncología Médica
Allergy
Angiology and Vascular Sugery
Cardiology
Cardiology department
Dermatology
Endocrinología y Nutrición
ESP011:Oncología Médica
Hematología
Hematology
Hospital Universitario de Jaén
HU de Jaén_Cardiología
Infectious Diseases
Internal Medicine
Medica Oncology
Medical Oncology
Medical Oncology Department
Medicina Interna
Oncolgy
Oncología
Oncología Médica
Oncology
Oncology department
Oncology service
Servicio de Angiología y Cirugía vascular
Servicio de Cardiologia
Servicio de Oncologia
Servicio de Oncología Médica
UCG Enfermedades Infecciosas, Microbiología y Medicina preventiva
UGC Cuidados Intensivos
Unidad de Gestion Clinica de Oncologia Medica
Urology
Vascular Risk

Clinical trials at this site (131)

Search interface

HARMONi-3 Not authorised

2023-504989-37-00 Metastatic Squamous Non-small Cell Lung Cancer 5
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending

2025-522791-92-00 Neoplasm Metastasis 5
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or… Pending

2025-523461-17-01 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANC 5
A Study to Learn about the Study Medicine called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive Stage Sma… Pending

2025-523522-41-00 Extensive-Stage Small Cell Lung Cancer 10
A Study to Learn about the Study Medicine called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers Pending

2025-523526-40-00 Advanced Solid Tumors 9
A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending

2025-523586-18-00 Non-Small Cell Lung Cancer 5
Phase II/III randomized controlled open-label trial to evaluate the efficacy and safety of personalized tissue engineered veins in patients … Pending

2025-524103-69-00 Chronic Venous Insufficiency 10
SIE-1 Recruiting

2025-523269-31-00 Hormone receptor-positive early breast cancer in post-m 3 2026-06-02
A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting

2025-524498-17-00 Pretreated Unresectable Locally Advanced or Metastatic 10 2026-05-08
Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g… Recruiting

2025-521314-25-00 NPM1-m and KMT2A-r Acute Myeloid Leukemia 5 2026-03-19
A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear… Recruiting

2023-505661-89-00 Early-stage, Hormone Receptor (HR)-positive / Human Epi 4 2025-12-19
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
A phase 2 placebo-controlled trial to investigate visugromab in combination with immunochemotherapy (ICT) in first-line treatment of partici… Recruiting

2024-516792-32-01 Metastatic non-squamous non-small cell lung cancer 4 2025-07-18
A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting

2024-512360-55-00 Unresectable locally recurrent or metastatic hormone re 4 2025-06-30
A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemal… Recruiting

2023-507097-41-01 Patients with limited-stage small cell lung cancer (LS- 5 2025-03-20
Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed… Recruiting

2024-512484-31-00 FGFR2b-positive, advanced or metastatic adenocarcinoma 4 2025-02-28
A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec… Recruiting

2024-512926-27-00 patients with estrogen receptor-positive/human epiderma 5 2024-12-12
Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized… Recruiting

2023-508441-41-00 Bacteriemia producida por P. aeruginosa. 6 2024-07-08
A Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors Recruiting

2023-510275-64-00 Hepatocellular carcinoma, colorectal cancer, endometria 9 2023-05-31
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 as monotherapy and in combination with bevacizum… Recruiting

2023-509335-60-00 Advanced solid tumors including (but not limited to), n 1 2023-02-23
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting

2023-505749-14-00 c-Met overexpressing EGFR wildtype non-squamous non-sma 5 2022-03-20
A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting

2023-509628-16-00 Small Cell Lung Cancer (SCLC) 5 2026-05-07